Zydus Lifesciences

Zydus undertakes not to commercially manufacture or launch Dabrafenib until Novartis' Indian patent expires in May 2029; statutory Bolar rights remain protected

Revenue from operations rose 22 per cent to Rs 8,017 crore, led by India formulations, consumer wellness and international markets, while EBITDA margin contracted

Q1FY27 company results: Firms including Manappuram Finance, Ashiana Housing, Ashoka Buildcon, Bata India, Balrampur Chini Mills, and Finolex Cables are also to release their April-June earnings today

USFDA has granted final approval to Zydus Lifesciences' generic version of IC-Green, an imaging agent used in vascular, transplant and cancer surgeries.

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Hitesh Rathi of Angel One recommends adopting a buy on dips approach for the Nifty, with prior resistance zone of 24,180-24,100 now likely to act as an immediate support cluster.

The joint venture will invest over $20 million in a pharmaceutical manufacturing facility in Sri Lanka to boost local drug production and reduce reliance on imports

Zydus Lifesciences and Sri Lanka's Sunshine Healthcare on Friday announced the setting up of a joint venture with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in the island nation. The company has entered into a share subscription and shareholders' agreement (SSSHA) with Sunshine Healthcare Lanka Ltd (Sunshine) and Zydus Sunshine Lifesciences (Pvt) Ltd (Zydus Sunshine), Zydus Lifesciences said in a regulatory filing. Under the SSSHA, Zydus Lifesciences will subscribe 50 per cent of the total paid-up equity share capital of Zydus Sunshine for up to USD 5 million in one or more tranches, it added. Zydus Sunshine will set up a manufacturing facility in Horana Export Processing Zone in Sri Lanka to manufacture pharmaceutical products, which will strengthen local production and reduce import dependence, the filing said. This will improve access to high-quality medicines while supporting national supply chain resilience, it ...

Strong domestic growth, an expanding specialty portfolio, acquisitions and a robust product pipeline are expected to support Zydus Lifesciences' performance in FY27

The pharmaceutical company said the buyback price has been increased from ₹1,150 per equity share to ₹1,260 per equity share

The US FDA has granted priority review to Saroglitazar, Zydus Lifesciences' drug for treating Primary Biliary Cholangitis

In the March quarter (Q4FY26), Zydus Lifesciences reported a net profit of ₹1,272.5 crore, as compared to ₹1,170.9 crore a year ago, up 8.7 per cent

Zydus Lifesciences reported strong fourth-quarter earnings growth, supported by robust performance in India, international markets, and consumer wellness

Q4FY26 company results: Firms including Zydus Lifesciences, BASF India, PI Industries, Zee Entertainment, and Bosch Home Comfort India are also to release their January-March earnings today

Zydus Wellness Ltd on Monday reported 5.75 per cent decline in consolidated net profit at Rs 162 crore for the fourth quarter ended March 31, 2026 impacted by higher expenses and taxes. The company had posted a net profit of Rs 171.9 crore for the year-ago period, Zydus Wellness said in a regulatory filing. Total revenue from operations in the fourth quarter stood at Rs 1,484.7 crore as compared to Rs 913.1 crore in the year-ago period. Total expenses were at Rs 1,308.6 crore as against Rs 740.5 crore. Total tax expenses were also higher at Rs 15.3 crore as compared to Rs 1.5 crore in March quarter FY25. In FY26, the consolidated net profit was at Rs 197.2 crore as compared to Rs 346.9 crore a year ago. Total revenue from operations stood at Rs 3,961 crore as against Rs 2,708.9 crore. The board of directors at its meeting held on May 18, 2026 recommended a final dividend of Rs 1.20 per equity share of Rs 2 each, subject to approval of the shareholders.

The buying on the counter came after the company, through a filing, said that its board will consider a buyback in a meeting along with the financial results on Tuesday, May 19, 2026

Acquisition gives Zydus a branded-drugs commercial platform in the US and strengthens its specialty pharmaceutical presence in pain and oncology therapies

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite